Literature DB >> 21390580

Therapeutic benefit of Yangxue Qingnao Granule on cognitive impairment induced by chronic cerebral hypoperfusion in rats.

Li Xiong1, Jun-Jian Zhang, Dong Sun, Hui Liu.   

Abstract

OBJECTIVE: To observe the therapeutic effect of Yangxue Qingnao Granule (, YXQNG) on cognitive impairment induced by chronic cerebral hypoperfusion and to investigate its impact on oxidative stress, apoptosis, and the cholinergic system.
METHODS: Adult male Wistar rats were subjected to chronic cerebral hypoperfusion by permanent occlusion of bilateral common carotid arteries (2-VO). Thirty rats were randomly assigned to one of the five treatment groups in a 1:1:1:1:1 ratio: sham operation plus normal saline treatment, 2-VO plus normal saline treatment, 2-VO plus YXQNG at a dose of 2 g·kg(-1)·d(-1) or 4 g·kg(-1)·d(-1), or 2-VO plus rivastigmine 2 mg·kg(-1)·d(-1). The Morris water maze test was used to assess the spatial memory retrieval. Apoptosis, total antioxide capacity (T-AOC), acetylcholine esterase (AchE) and choline acetyl transferase (ChAT) activities in the hippocampus and the cortex were investigated.
RESULTS: In the chronic cerebral hypoperfusion model, the 2-VO plus saline treatment resulted in impaired special learning as shown by the significantly prolonged escape latency and shorter swim time in the first quadrant as compared to the sham operation. The impairment was associated with apoptosis and significant decreases in T-AOC, AchE and ChAT activities in the hippocampus and the cortex. Treatment with YXQNG at either 2 g·kg(-1)·d(-1) or 4 g·kg(-1)·d(-1) dose, or rivastigmine resulted in significantly shorter escape latencies and longer swim time in the first quadrant. YXQNG at both doses, but not rivastigmine, had significant reduction in apoptosis, and significant increases in T-AOC and ChAT activity in both the hippocampus and the cortex. Unlike rivastigmine, neither dose of YXQNG showed significant reduction in AchE activity.
CONCLUSIONS: YXQNG ameliorated cognitive impairment induced by chronic cerebral hypoperfusion. The protective effect may be mediated through its regulation of apoptosis and activities of T-AOC and ChAT in the hippocampus and cortex of the rats in the chronic cerebral hypoperfusion model, a mechanism that is different from rivastigmine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390580     DOI: 10.1007/s11655-011-0643-0

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  13 in total

1.  Chronic cerebrovascular insufficiency induces dementia-like deficits in aged rats.

Authors:  J C de la Torre; T Fortin; G A Park; K S Butler; P Kozlowski; B A Pappas; H de Socarraz; J K Saunders; M T Richard
Journal:  Brain Res       Date:  1992-06-12       Impact factor: 3.252

Review 2.  The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia.

Authors:  Costantino Iadecola
Journal:  Acta Neuropathol       Date:  2010-07-11       Impact factor: 17.088

3.  Altered expression of MAP-2, GAP-43, and synaptophysin in the hippocampus of rats with chronic cerebral hypoperfusion correlates with cognitive impairment.

Authors:  Han-Xing Liu; Jun-Jian Zhang; Ping Zheng; Yi Zhang
Journal:  Brain Res Mol Brain Res       Date:  2005-09-13

4.  The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.

Authors:  George S Alexopoulos; Dilip V Jeste; Henry Chung; Daniel Carpenter; Ruth Ross; John P Docherty
Journal:  Postgrad Med       Date:  2005-01       Impact factor: 3.840

Review 5.  Cognitive impairment and chronic cerebral hypoperfusion: what can be learned from experimental models.

Authors:  Cristina Sarti; Leonardo Pantoni; Luciano Bartolini; Domenico Inzitari
Journal:  J Neurol Sci       Date:  2002-11-15       Impact factor: 3.181

6.  Chronic cerebral hypoperfusion elicits neuronal apoptosis and behavioral impairment.

Authors:  S A Bennett; M Tenniswood; J H Chen; C M Davidson; M T Keyes; T Fortin; B A Pappas
Journal:  Neuroreport       Date:  1998-01-05       Impact factor: 1.837

7.  Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion.

Authors:  K Tanaka; N Ogawa; M Asanuma; Y Kondo; M Nomura
Journal:  Brain Res       Date:  1996-08-05       Impact factor: 3.252

8.  Study on Yangxue Qingnao granule in treating chronic cerebrovascular insufficiency.

Authors:  Xi-xi Gu; Ding-fang Cai; Yun-ke Yang; Ying Teng; Yi-ping Chen; Ming Wen
Journal:  Chin J Integr Med       Date:  2005-03       Impact factor: 1.978

Review 9.  Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease.

Authors:  Paula Agostinho; Rodrigo A Cunha; Catarina Oliveira
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 10.  The enigma of vascular cognitive disorder and vascular dementia.

Authors:  Kurt A Jellinger
Journal:  Acta Neuropathol       Date:  2007-02-07       Impact factor: 17.088

View more
  5 in total

1.  Cerebralcare Granule(®), a Chinese Herb Compound Preparation, Attenuates D-Galactose Induced Memory Impairment in Mice.

Authors:  Zhuo Qu; Honggai Yang; Jingze Zhang; Liqin Huo; Hong Chen; Yuming Li; Changxiao Liu; Wenyuan Gao
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

2.  YXQN Reduces Alzheimer's Disease-Like Pathology and Cognitive Decline in APPswePS1dE9 Transgenic Mice.

Authors:  Xiaowan Wang; Runmin Song; Wenliang Lu; Ziyu Liu; Lichun Wang; Xiaojuan Zhu; Yanjun Liu; Zijie Sun; Jiang Li; Xiaomeng Li
Journal:  Front Aging Neurosci       Date:  2017-05-23       Impact factor: 5.750

3.  Radix Ilicis Pubescentis total flavonoids ameliorates neuronal damage and reduces lesion extent in a mouse model of transient ischemic attack.

Authors:  Ming-San Miao; Lin Guo; Rui-Qi Li; Xiao-Lei Zhang
Journal:  Neural Regen Res       Date:  2016-03       Impact factor: 5.135

4.  Cerebralcare Granule® attenuates cognitive impairment in rats continuously overexpressing microRNA-30e.

Authors:  Yong Xu; Zhifen Liu; Xi Song; Kerang Zhang; Xingrong Li; Jianhong Li; Xu Yan; Yuan Li; Zhongchen Xie; Hui Zhang
Journal:  Mol Med Rep       Date:  2015-10-22       Impact factor: 2.952

5.  Mechanism of Cerebralcare Granule® for Improving Cognitive Function in Resting-State Brain Functional Networks of Sub-healthy Subjects.

Authors:  Jing Li; Hao Guo; Ling Ge; Long Cheng; Junjie Wang; Hong Li; Kerang Zhang; Jie Xiang; Junjie Chen; Hui Zhang; Yong Xu
Journal:  Front Neurosci       Date:  2017-07-14       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.